ChemoCentryx, Inc. announced that it expects to receive $100 million in funding from Vifor Fresenius Medical Care Renal Pharma Ltd., Fresenius Medical Care AG & Co. KGAA, Hercules Capital, Inc.

ChemoCentryx, Inc. (NasdaqGS:CCXI) announced a private placement of $100 million on January 4, 2017. The company will receive $50 million from Vifor Fresenius Medical Care Renal Pharma Ltd., Fresenius Medical Care AG & Co. KGAA (XTRA:FME) and $50 million credit facility from Hercules Capital, Inc. (NYSE:HTGC).

The Credit facility will receive in three tranches. The company will receive $15 million first tranche, and $35 million will receive in two additional tranches. The term loan has a 24-month interest-only period from initial funding, which is extendable to 30 months upon the achievement of certain milestones and matures in 48 months.

The company has raised $155 million in funding till date.